NASDAQ:HALO - Halozyme Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$16.43 +0.13 (+0.80 %)
(As of 01/20/2019 04:00 PM ET)
Previous Close$16.43
Today's Range$16.07 - $16.59
52-Week Range$13.24 - $21.48
Volume640,578 shs
Average Volume725,644 shs
Market Capitalization$2.38 billion
P/E Ratio36.51
Dividend YieldN/A
Beta1.72
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:HALO
CUSIP40637H10
Phone858-794-8889

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$316.61 million
Cash Flow$0.4554 per share
Book Value$1.46 per share

Profitability

Net Income$62.97 million

Miscellaneous

Employees255
Market Cap$2.38 billion
OptionableOptionable

Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. The biopharmaceutical company earned $25.60 million during the quarter, compared to analyst estimates of $30.42 million. Halozyme Therapeutics had a net margin of 16.24% and a return on equity of 18.87%. Halozyme Therapeutics's revenue for the quarter was down 59.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.02 earnings per share. View Halozyme Therapeutics' Earnings History.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Halozyme Therapeutics.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics issued an update on its FY 2018 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $150-160 million, compared to the consensus revenue estimate of $126.97 million.

What price target have analysts set for HALO?

8 brokers have issued 1 year price targets for Halozyme Therapeutics' stock. Their predictions range from $17.00 to $27.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $21.00 in the next year. This suggests a possible upside of 27.8% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics.

What is the consensus analysts' recommendation for Halozyme Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Halozyme Therapeutics.

What are Wall Street analysts saying about Halozyme Therapeutics stock?

Here are some recent quotes from research analysts about Halozyme Therapeutics stock:
  • 1. According to Zacks Investment Research, "Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine. " (1/18/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month price target of $27/share of Halozyme. We recently hosted investors for a meeting with HALO management on our Post ASH-Thrash Bus Tour. Interest remains high in the core ENHANZE business and potential new partners, but also expansion of clinical-stage development candidates with current partners. Recall that the agreements with current partners include multiple candidates for which only a fraction have entered the clinic. Companies have started to understand the potential benefits of ENHANZE, such as the ability to take daratumumab, which currently requires a 4-6 hour IV infusion, down to a 3-5 minute injection." (12/5/2018)

Has Halozyme Therapeutics been receiving favorable news coverage?

News coverage about HALO stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Halozyme Therapeutics earned a news impact score of -1.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.

Who are some of Halozyme Therapeutics' key competitors?

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the folowing people:
  • Dr. Helen I. Torley, Pres, CEO & Director (Age 56)
  • Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)
  • Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)
  • Mr. Ed Gemo, VP, Chief Information & Security Officer
  • Mr. Albert S. Kildani, VP of Investor Relations & Corp. Communications

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Taylor Wealth Management Partners (0.14%) and Fox Run Management L.L.C. (0.01%). View Institutional Ownership Trends for Halozyme Therapeutics.

Which major investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including Taylor Wealth Management Partners and Fox Run Management L.L.C.. View Insider Buying and Selling for Halozyme Therapeutics.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $16.43.

How big of a company is Halozyme Therapeutics?

Halozyme Therapeutics has a market capitalization of $2.38 billion and generates $316.61 million in revenue each year. The biopharmaceutical company earns $62.97 million in net income (profit) each year or $0.45 on an earnings per share basis. Halozyme Therapeutics employs 255 workers across the globe.

What is Halozyme Therapeutics' official website?

The official website for Halozyme Therapeutics is http://www.halozyme.com.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]


MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  340 (Vote Outperform)
Underperform Votes:  298 (Vote Underperform)
Total Votes:  638
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel